Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.


In the US, Abarelix is a member of the following drug classes: gonadotropin-releasing hormone antagonists, hormones/antineoplastics and is used to treat Prostate Cancer.



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Gonadotropin releasing hormone (GnRH) receptor antagonist

Chemical Name

N-Acetyl-3-(2-naphtyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-metyl-L-tyrosyl-D-asparaginyl-L-leucyl-N⁶-isopropyl-L-lysyl-L-prolyl-D-alaninamide (WHO)

Foreign Names

  • Abarelixum (Latin)
  • Abarelix (German)
  • Abarelix (French)
  • Abarelix (Spanish)

Generic Names

  • Abarelix (OS: USAN)
  • PPI 149 (IS: Praecis)
  • R 3827 (IS: Praecis)

Brand Names

  • Plenaxis
    EuroCept, Netherlands; Speciality European Pharma, Germany


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.